eIF4E Inhibitor Compounds for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders associated with dysregulated eukaryotic initiation factor 4E (eIF4E, such as cancer, lack effective inhibitors that specifically target eIF4E, leading to inadequate therapeutic outcomes.
Innovation Solution
Development of compounds, represented by Formula (I) and their pharmaceutically acceptable salts, which act as eIF4E inhibitors by binding to and inhibiting the activity of eIF4E, thereby treating various diseases including cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for disorders associated with dysregulated eIF4E, then general cancer treatment is provided, but specific eIF4E inhibition is not achieved leading to inadequate therapeutic outcomes
Solution Approach 1:
The patent develops small molecule compounds with specific chemical structures (Formula I) that are designed to bind to eIF4E with high affinity and selectivity. By changing the chemical parameters and molecular structure of the inhibitors, the compounds achieve specific inhibition of eIF4E while maintaining therapeutic efficacy, thereby resolving the contradiction between general treatment approach and specific target inhibition.
2Reliability
If eIF4E is targeted specifically with novel compounds, then therapeutic efficacy is improved, but the complexity of drug development and validation increases
Solution Approach 1:
The patent segments the drug development process into distinct phases: identification of eIF4E as a target, design of small molecule compounds with specific structures (Formula I), in vitro validation of inhibition, in vivo efficacy testing in cancer models, and characterization of selectivity. This segmentation allows systematic advancement from target identification to therapeutic validation, managing complexity through structured development stages.
Solution Approach 2:
The patent performs preliminary actions by first identifying eIF4E as a dysregulated target in cancer, then designing and synthesizing compounds with predicted eIF4E binding capability before full validation. The compounds are preliminarily tested in vitro to confirm inhibition, and then advanced to in vivo studies, allowing early filtering of ineffective candidates before committing to extensive development resources.
Data Source
AI summary
The present invention provides compounds inhibiting eIF4E activity, and compositions and methods of using thereof.